Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry

doi:10.1111/myc.13067

. 2020 May;63(5):437-442.

doi: 10.1111/myc.13067. Epub 2020 Apr 15.

Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope^® registry

Jeffrey D Jenks^{1

2}, Danila Seidel³, Oliver A Cornely³, Sharon Chen⁴, Sebastiaan van Hal⁵, Carol Kauffman⁶, Marisa H Miceli⁶, Melina Heinemann⁷, Martin Christner⁸, Alfredo Jover Sáenz⁹, Alexander Burchardt¹⁰, Björn Kemmerling¹⁰, Raoul Herbrecht¹¹, Joerg Steinmann^{12

13}, Shmuel Shoham¹⁴, Sandra Gräber¹⁵, Livio Pagano¹⁶, Dries Deeren¹⁷, Monica A Slavin¹⁸, Martin Hoenigl^{1

2

19}

Affiliations

¹ Department of Medicine, University of California San Diego, San Diego, CA, USA.
² Clinical and Translational Fungal Research Group, University of California San Diego, San Diego, CA, USA.
³ Department I of Internal Medicine, ECMM Excellence Centre of Medical Mycology, CECAD-Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University Hospital Cologne, Cologne, Germany.
⁴ Sydney Medical School, Centre for Infectious Diseases and Microbiology, Westmead Hospital, The University of Sydney, Camperdown, New South Wales, Australia.
⁵ Department of Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁶ Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
⁷ Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁸ Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁹ Territorial Unit of Nosocomial Infection and antibiotic policy (TUNI), University Hospital Arnau de Vilanova, Lleida, Spain.
¹⁰ Department of Hematology, Hospital of Justus Liebig University, Giessen, Germany.
¹¹ Department of Oncology and Hematology, Strasbourg University Hospital, Strasbourg, France.
¹² Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany.
¹³ Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
¹⁴ Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹⁵ Institute of Medical Microbiology and Epidemiology of Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.
¹⁶ Department of Hematology, Fondazione Policlinico A. Gemelli - IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
¹⁷ Department of Hematology, AZ Delta, Roeselare, Belgium.
¹⁸ Department of Infectious Diseases, Peter MacCallum Cancer Centre, National Centre for Infections in Cancer, Melbourne, Vic., Australia.
¹⁹ Department of Medicine, ECMM Excellence Centre of Medical Mycology, Medical University of Graz, Graz, Austria.

PMID: 32080902
DOI: 10.1111/myc.13067

Free article

Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope^® registry

Jeffrey D Jenks et al. Mycoses. 2020 May.

Free article

. 2020 May;63(5):437-442.

doi: 10.1111/myc.13067. Epub 2020 Apr 15.

Authors

Affiliations

¹ Department of Medicine, University of California San Diego, San Diego, CA, USA.
² Clinical and Translational Fungal Research Group, University of California San Diego, San Diego, CA, USA.
³ Department I of Internal Medicine, ECMM Excellence Centre of Medical Mycology, CECAD-Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University Hospital Cologne, Cologne, Germany.
⁴ Sydney Medical School, Centre for Infectious Diseases and Microbiology, Westmead Hospital, The University of Sydney, Camperdown, New South Wales, Australia.
⁵ Department of Microbiology and Infectious Diseases, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁶ Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
⁷ Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁸ Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁹ Territorial Unit of Nosocomial Infection and antibiotic policy (TUNI), University Hospital Arnau de Vilanova, Lleida, Spain.
¹⁰ Department of Hematology, Hospital of Justus Liebig University, Giessen, Germany.
¹¹ Department of Oncology and Hematology, Strasbourg University Hospital, Strasbourg, France.
¹² Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany.
¹³ Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
¹⁴ Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹⁵ Institute of Medical Microbiology and Epidemiology of Infectious Diseases, University Hospital Leipzig, Leipzig, Germany.
¹⁶ Department of Hematology, Fondazione Policlinico A. Gemelli - IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
¹⁷ Department of Hematology, AZ Delta, Roeselare, Belgium.
¹⁸ Department of Infectious Diseases, Peter MacCallum Cancer Centre, National Centre for Infections in Cancer, Melbourne, Vic., Australia.
¹⁹ Department of Medicine, ECMM Excellence Centre of Medical Mycology, Medical University of Graz, Graz, Austria.

PMID: 32080902
DOI: 10.1111/myc.13067

Abstract

Objectives: Invasive fungal infections caused by Lomentospora prolificans are associated with very high mortality rates and can be challenging to treat given pan-drug resistance to available antifungal agents. The objective of this study was to describe the clinical presentation and outcomes in a cohort of patients with invasive L prolificans infections.

Methods: We performed a retrospective review of medical records of patients with invasive L prolificans infection in the FungiScope^® registry of rare invasive fungal infections. Patients diagnosed between 01 January 2008 and 09 September 2019 were included in for analysis.

Results: The analysis included 41 patients with invasive L prolificans infection from eight different countries. Haematological/oncological malignancies were the most frequent underlying disease (66%), disseminated infection was frequent (61%), and the lung was the most commonly involved organ (44%). Most infections (59%) were breakthrough infections. Progression/deterioration/treatment failure was observed in 23/40 (58%) of patients receiving antifungal therapy. In total, 21/41 (51%) patients, and 77% of patients with underlying haematological/oncological malignancy, had a fatal outcome attributed to invasive fungal infection. Combination antifungal therapy was frequent (24/40) and associated with improved survival. In particular, treatment regimens including terbinafine were significantly associated with higher treatment success at final assessment (P = .012), with a positive trend observed for treatment regimens that included voriconazole (P = .054).

Conclusions: Lomentospora prolificans infections were associated with mortality rates of 77% and above in patients with underlying haematological/oncological malignancies and those with disseminated infections. While combination therapy is the preferred option for now, the hope lies with novel antifungals currently under development.

Keywords: Lomentospora prolificans; clinical presentation; fungal infections; outcomes; treatment.

PubMed Disclaimer

Cited by

Race and ethnicity: Risk factors for fungal infections?
Jenks JD, Aneke CI, Al-Obaidi MM, Egger M, Garcia L, Gaines T, Hoenigl M, Thompson GR 3rd. Jenks JD, et al. PLoS Pathog. 2023 Jan 5;19(1):e1011025. doi: 10.1371/journal.ppat.1011025. eCollection 2023 Jan. PLoS Pathog. 2023. PMID: 36602962 Free PMC article. Review.
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR 3rd, Wiederhold N, Jenks JD. Hoenigl M, et al. Drugs. 2021 Oct;81(15):1703-1729. doi: 10.1007/s40265-021-01611-0. Epub 2021 Oct 9. Drugs. 2021. PMID: 34626339 Free PMC article. Review.
Universal digital high-resolution melting for the detection of pulmonary mold infections.
Goshia T, Aralar A, Wiederhold N, Jenks JD, Mehta SR, Karmakar A, E S M, Sharma A, Sun H, Kebadireng R, White PL, Sinha M, Hoenigl M, Fraley SI. Goshia T, et al. J Clin Microbiol. 2024 Jun 12;62(6):e0147623. doi: 10.1128/jcm.01476-23. Epub 2024 May 2. J Clin Microbiol. 2024. PMID: 38695528 Free PMC article.
Deciphering Unexpected Vascular Locations of Scedosporium spp. and Lomentospora prolificans Fungal Infections, France.
Vignals C, Emmerich J, Begueret H, Garcia-Hermoso D, Martin-Blondel G, Angoulvant A, Blez D, Bruneval P, Cassaing S, Catherinot E, Cahen P, Moluçon-Chabrot C, Chevenet C, Delhaes L, Escaut L, Faruch M, Grenouillet F, Larosa F, Limousin L, Longchampt E, Mellot F, Nourrisson C, Bougnoux ME, Lortholary O, Roux A, Rozenblum L, Puges M, Lanternier F, Bronnimann D. Vignals C, et al. Emerg Infect Dis. 2024 Jun;30(6):1077-1087. doi: 10.3201/eid3006.231409. Emerg Infect Dis. 2024. PMID: 38781681 Free PMC article. Review.
Invasive mold infection of the gastrointestinal tract: A case series of 22 immunocompromised patients from a single academic center.
Quintero O, Allard L, Ho D. Quintero O, et al. Med Mycol. 2022 Mar 4;60(3):myac007. doi: 10.1093/mmy/myac007. Med Mycol. 2022. PMID: 35092429 Free PMC article.

See all "Cited by" articles

References

REFERENCES

1. Cobo F, Lara-Oya A, Rodriguez-Granger J, Sampedro A, Aliaga-Martinez L, Navarro-Mari JM. Infections caused by Scedosporium/Lomentospora species: clinical and microbiological findings in 21 cases. Medical mycology. 2018;56(8):917-925.
1. Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis. 2007;13(8):1170-1177.
1. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis. 2006;43(12):1580-1584.
1. Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52(5):706-712.
1. Ramirez-Garcia A, Pellon A, Rementeria A, et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. Med Mycol. 2018;56(Suppl_1):S102-S125.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Supplementary concepts

Actions

Grants and funding

LinkOut - more resources

Full Text Sources

[1] Cobo F, Lara-Oya A, Rodriguez-Granger J, Sampedro A, Aliaga-Martinez L, Navarro-Mari JM. Infections caused by Scedosporium/Lomentospora species: clinical and microbiological findings in 21 cases. Medical mycology. 2018;56(8):917-925.

[2] Cobo F, Lara-Oya A, Rodriguez-Granger J, Sampedro A, Aliaga-Martinez L, Navarro-Mari JM. Infections caused by Scedosporium/Lomentospora species: clinical and microbiological findings in 21 cases. Medical mycology. 2018;56(8):917-925.

[3] Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis. 2007;13(8):1170-1177.

[4] Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis. 2007;13(8):1170-1177.

[5] Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis. 2006;43(12):1580-1584.

[6] Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis. 2006;43(12):1580-1584.

[7] Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52(5):706-712.

[8] Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52(5):706-712.

[9] Ramirez-Garcia A, Pellon A, Rementeria A, et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. Med Mycol. 2018;56(Suppl_1):S102-S125.

[10] Ramirez-Garcia A, Pellon A, Rementeria A, et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. Med Mycol. 2018;56(Suppl_1):S102-S125.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope^® registry

Affiliations

Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope^® registry

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

REFERENCES

MeSH terms

Substances

Supplementary concepts

Related information

Grants and funding

LinkOut - more resources

Full Text Sources